Contents lists available at ScienceDirect



Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Endogenous retrovirus ERV-DC8 highly integrated in domestic cat populations is a replication-competent provirus

Didik Pramono^{a, b, 1}, Yutaro Muto^{a, 1}, Yo Shimazu^a, R.M.C. Deshapriya^c, Isaac Makundi^d, MaríaCruz Arnal^e, Daniel Fernández de Luco^e, Minh Ha Ngo^f, Ariko Miyake^{a, b}, Kazuo Nishigaki^{a, b,*}

^a Laboratory of Molecular Immunology and Infectious Disease, Joint Graduate School of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan

^c Department of Animal Science, Faculty of Agriculture, University of Peradeniya, Peradeniya, 20400, Sri Lanka

^d Department of Microbiology, Parasitology and Biotechnology, College of Veterinary Medicine and Biomedical Sciences, Sokoine University of Agriculture, P.O. Box

^e Departamento de Patología Animal, Facultad de Veterinaria, Universidad de Zaragoza, C/ Miguel Servet, 177 50013, Zaragoza, Spain

^f Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, N6A 3K7, Canada

ARTICLE INFO

Keywords: ERV-DC FeLV Endogenous retrovirus Domestic cat

ABSTRACT

Endogenous retroviruses (ERVs) are remnants of ancient retroviral infections in vertebrate genomes and are inherited by offspring. ERVs can produce pathogenic viruses through gene mutations or recombination. ERVs in domestic cats (ERV-DCs) generate feline leukemia virus subgroup D (FeLV-D) through viral recombination. Herein, we characterized the locus ERV-DC8, on chromosome B1, as an infectious replication-competent provirus. ERV-DC8 infected several cell lines, including human cells. Transmission electron microscopy of ERV-DC8 identified the viral release as a *Gammaretrovirus*. ERV-DC8 was identified as the FeLV-D viral interference group, with feline copper transporter 1 as its viral receptor. Insertional polymorphism analysis showed high ERV-DC8 integration in domestic cats. This study highlights the role, pathogenicity, and evolutionary relationships between ERVs and their hosts.

1. Introduction

Endogenous retroviruses (ERVs) are remnants of ancient retroviral infections and comprise approximately 4–10 % of the human, mouse, and cat genomes [1–3]. The invasion of germ cells causes endogenization via vertical transmission of the provirus to the offspring. Numerous ERVs are inactivated by the accumulation of mutations such as nucleotide sequence substitutions, insertions, and deletions, and/or by the loss of transcriptional activity due to epigenetic control [4,5]. These events may be related to viral integration time. Therefore, most ERVs exist as non-functional DNA. However, some endogenous retroviruses retain their infectivity and ability to replicate [6,7]. Additionally, both pathogenic and emerging viruses are generated by gene mutations or recombination [8]. Various diseases associated with ERV have been

reported in mice and humans [9,10].

The feline leukemia virus (FeLV) is a pathogenic *Gammaretrovirus* that causes various pathological conditions in domestic cats, including proliferative and immune diseases. FeLV subgroups are classified according to viral entry based on receptor differences. FeLV subgroup A (FeLV-A) is the most common and is horizontally transmitted between hosts via grooming or biting [11]. A novel FeLV, namely FeLV subgroup D (FeLV-D), has been identified in cases of feline lymphoma and leukemia [7,12]. FeLV-D was generated by the recombination of ERV of domestic cats (ERV-DCs) genotype I (GI) in the *env* region with FeLV [7], demonstrated a distinct tropism compared with other identified FeLV subgroups [7] and belonged to a different interference group. In addition, recombination between ERV-DCs and baboon endogenous retrovirus (BaEV) generated RD-114, another distinct feline retrovirus. This

https://doi.org/10.1016/j.bbrc.2024.150521

Received 20 June 2024; Received in revised form 31 July 2024; Accepted 7 August 2024 Available online 9 August 2024 0006-291X/© 2024 The Authors. Published by Elsevier Inc. This is an open access article

^b Research Institute for Cell Design Medical Science, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan

^{3019,} Morogoro, 67125, Tanzania

^{*} Corresponding author. Laboratory of Molecular Immunology and Infectious Disease, Joint Graduate School of Veterinary Medicine, Yamaguchi University, 1677Yoshida, Yamaguchi, 753-8515, Japan.

E-mail address: kaz@yamaguchi-u.ac.jp (K. Nishigaki).

¹ These authors contributed equally to this work.

⁰⁰⁰⁶⁻²⁹¹X/© 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

D. Pramono et al.

recombination event supports interspecies retroviral transmission between cats and primates [7,13–15] and reinforces that the interactions between exogenous retroviruses and ERVs contribute to long-term retroviral diversification and evolution.

ERV-DC is an endogenous Gammaretrovirus of the domestic cat. In the last decade, ERV-DCs have been characterized and identified as young ERVs, estimated to have integrated into the host genome approximately 2.8 million years ago (MYA) [7]. Thirteen loci of ERV-DC have been reported in the cat (Felis silvestris catus) genome [7]. ERV-DCs are phylogenetically classified into genotypes I-III (GI, GII, and GIII). ERV-DCs typically have simple retroviral structures consisting of gag, pol, and env genes flanked by two long terminal repeats (LTRs) approximately 9 kb in length in the viral genome [7]. Among the 13 ER V-DCs, ERV-DC8 (GI), ERV-DC10 (GIII), ERV-DC14 (GI), and ERV-DC18 (GIII) have intact open reading frames (ORFs). ERV-DC10, ERV-DC14, and ERV-DC18 can produce infectious viral particles that are characteristic of pantropic and xenotropic viruses [7]. However, whether ERV-DC8 is replication-competent remains unclear. Notably, ERV-DCs are known to retain their ability to potentially affect their hosts via viral activity and contribute to the emergence of recombinant viruses. Here, we characterized, from a cat sample, ERV-DC8, its ability to infect various host cells, and its integration frequency in domestic cats.

2. Materials and methods

2.1. Animals and sampling

We used the DNA genome of the domestic cat sample (cat IDs: CB7, OY20, and OI32) [16] and DNA samples from domestic cats in countries, namely, South Korea, Vietnam, Sri Lanka, Tanzania, Japan, and Spain that have been described previously [17].

2.2. Cell cultures

The cells used in this study were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM FUJIFILM; Wako Pure Chemical Corporation, Osaka, Japan) supplemented with 10 % fetal calf serum (FCS) and 1X penicillin-streptomycin and incubated in a CO₂ incubator at 37 °C. The following cell types were used: HepG2 (human liver cancer) [18], HEK293T (human embryonic kidney transformed by SV40 large T antigen) [19], AH927 (feline fibroblast cells) [20] CRFK (feline kidney) [21], KwDM (canine mammary gland tumor) [7], Rat2 (RAT-1 [F2408]-cell-derived, thymidine kinase-deficient mutant Rat2 cells) [22], 104C1 (guinea pig, fetal origin) [23], MDTF (Mus dunni fibroblast tail) [24], HEK293T cells persistently infected with FeLV-D (293T/FeLV-D cells) [7], 293Lac cells containing a pMXs retroviral vector carrying a LacZ marker [25], and MDTF expressing feline copper transporter 1 (MDTF-feCTR1) cells [26]. Briefly, MDTF cells were transfected with expression vectors (pFUAss-feCTR1 or pFUAss empty vector as a control) using Lipofectamine®3000 (Thermo Fisher Scientific, Waltham, MA, USA). Single cells were cultured in medium containing 200 µg/mL zeocin (InvivoGen, San Diego, CA, USA) in 96-well plates and single cells were isolated. These cells were designated MDTF-feCTR1 and MDTF-empty for further analysis.

2.3. Cloning of the ERV-DC8 provirus

The DNA genome of domestic cats (cat IDs: CB7, OY20, and OI32) were used to detect the ERV-DC8 provirus using locus-specific PCR. PCR was performed using KOD One PCR Master Mix (Toyobo, Osaka, Japan), according to the manufacturer's instructions. Fe–57S (5'-TTAGAGGAA-TAAGCTCGGGGTAACT-3') was used as the forward primer, and Fe-54R (5'-GGTGCTCATTGTTAGGAGAGAAAAA-3') was used as the reverse primer. The primers were designed to target the flanking region of the ERV-DC8 provirus with a predicted PCR amplicon size of approximately 9 kb. The cycling conditions were as follows: 35 cycles of denaturation at

98 °C for 10 s, annealing at 60 °C for 5 s, and extension at 68 °C for 100 s. The PCR products were electrophoresed on a 1 % agarose gel, stained with ethidium bromide solution, and visualized using a UV transilluminator. The amplified PCR fragment was cloned using pCR 4 Blunt-TOPO (Invitrogen, Waltham, MA, USA). ERV-DC8 OI32 (cat ID: OI32), which carries a heterologous ERV-DC8, was the ERV-DC8 clone used. The resulting plasmids were confirmed using sequencing (Fasmac Corporation, Atsugi, Japan).

2.4. Construction of the ERV-DC8TA mutant

Sequence analysis and alignment with ERV-DC were performed as previously described [7]. A mutant ERV-DC was constructed with thymine (T) replaced with an adenine (A) at nucleotide positions 280 in the 5'LTR and 8594 in the 3'LTR of ERV-DC8 (OI32). The ERV-DC8TA mutant was constructed by site-directed mutagenesis using KOD One PCR Master Mix (Toyobo, Osaka, Japan) with the primers pair DC8-mu6S (5'-CTCCAAGTTGCATCAGCCGAGAGAAACTCC-3') and DC8-mu6R (5'-GGAGTTTCTCTCGGCTGATGCAACTTGGAG-3').

2.5. Virus preparation

The plasmids were transfected into 293Lac cells using TransIT®-293 Transfection Reagent (Takara, Shiga, Japan). After 3 days, the supernatant was collected and filtered through a 0.22 μ m filter (Merck, Darmstadt, Germany) to prepare a viral stock, and stored at -80 °C for further experiments.

2.6. Infection assay

Approximately 3×10^5 cells/well were seeded in 24-well plates one day before infection. Each well was inoculated with 250 µL of the virus in the presence of 8 µg/mL polybrene (Nacalai Tesque, Kyoto, Japan) for 2 h. After adding fresh medium, the cells were cultured for 3 days postinfection. For the LacZ assay, culture supernatants were removed and cells were fixed with 250 µL of 2 % glutaraldehyde for 15 min at room temperature (20–25 °C), followed by the addition of 250 µL of 5-bromo-4-chloro-3-indolyl- β -p-galactopyranoside (X-gal) solution to stain cells. After incubation at 37 °C for 2 h, the nuclei in LacZ-positive cells were counted under a microscope. Viral titers were expressed as infectious units (IU) per mL. The standard deviations were calculated.

2.7. Viral protein preparation

Plasmids were transfected into 293T cells using TransIT®-293 Transfection Reagent. Transfected ERV-DC10 cells were used as positive controls, whereas non-transfected 293T cells were used as negative controls. The cell lysates were prepared by collecting cell pellets 48 and 72 h after transfection and adding them to cell lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 10 % glycerol, 1 % NP-40, 2 mM EDTA, 1 mM Na3VO4, 1 µg/mL aprotinin, and 1 µg/mL leupeptin) on ice for 20 min and centrifuging at 15,400×g for 20 min at 4 °C. The protein concentrations were calculated using a protein assay kit (Bio-Rad, Hercules, CA, USA).

For viral purification, cell supernatants were collected 48 and 72 h after transfection. The supernatant (4 mL) was ultracentrifuged at 29000×g for 90 min at 4 °C, and the virus pellet was collected in phosphate-buffered saline (PBS) and stored at -80 °C until use.

2.8. Western blotting

To obtain a sample from protein purification, sample buffer (6 \times) (Nacalai Tesque, Kyoto, Japan) containing 2-mercaptoethanol (FUJI-FILM Wako Pure Chemical Corporation) was added and heated at 95–100 °C for 5 min. Subsequently, SDS-PAGE was performed using a 7.5 % gel (Oriental Instruments Co., Ltd.; Sagamihara, Japan) or 4–20 %



Fig. 1. Infection assay of ERV-DC8. (A) 293Lac cells were transfected with ERV-DC8-containing plasmid or were mock transfected, and the supernatants were collected and used to infect KwDM cells. (B) HepG2 (human), KwDM (dog), Rat2 (rat), 104C1 (guinea pig), and MDTF (mouse) as target cells were inoculated with ERV-DC8 replication-competent virus. The infectious units were determined by counting the number of log10-galactosidase (LacZ)-positive cells per milliliter of virus. Mean virus infection titers with standard deviations were determined from three independent experiments. (C) Western blot analysis of ERV-DC Envs proteins in 293Lac cells using anti-FeLV gp70. Actin was used as a control. (D) ERV-DC8 Env protein was detected in purified virions from the supernatant of HEK293T cells transfected with ERV-DC8 at 2 and 3 days post-transfection. ERV-DC10 was used as the positive control. Mock cells were used as the negative control. Anti-FeLV gp70 was used for western blotting, whereas anti-human β-actin was used as the control. Red asterisks indicate Env proteins. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

gel (Invitrogen, Carlsbad, CA, USA) at 100 V for 2 h. The separated protein bands were detected using a primary goat anti-FeLV gp70 polyclonal antibody (National Cancer Institute [NCI], Frederick, MD, USA; dilution 1:15000) as the primary antibody, which cross-reacts with ERV-DC Env and mouse monoclonal anti-human β -actin (Santa Cruz Biotechnology, Dallas. TX). The secondary antibodies used were horse-radish peroxidase (HRP)-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology; 1:10000) or HRP-conjugated anti-mouse IgG (Cell Signaling Technology, Danvers, MA, USA). LumiGLO @ Reagent (20 ×) and 20 × peroxide (Cell Signaling Technology, Danvers, MA, USA) were used as substrates for signaling using a Lumino Image Analyzer LAS2000 (Fujifilm, Tokyo, Japan).

2.9. Transmission electron microscopy (TEM)

TEM was performed as previously described [7]. Briefly, HEK293T cells transfected with the ERV-DC8TA plasmid were fixed at room temperature for 10 min by adding 2 % glutaraldehyde in PBS, and then further fixed at 4 °C for 2 h. Cells were washed with Dulbecco's phosphate-buffered saline (D-PBS) (twice for 15 min each), and fixed with 2 % osmium tetroxide for 1.5 h. Cells were dehydrated using a graded ethanol series and propylene oxide and then Epon 812-embedded for 48 h at 60 °C. Ultrathin sections were stained with uranyl acetate and lead citrate. Viral particles were analyzed using a

transmission electron microscope at the Hanaichi Electron Microscope Technology Research Institute Co., Ltd. (Aichi, Japan).

2.10. ERV-DC8 insertional polymorphism

Chromosomal DNA from domestic cats from Vietnam, Sri Lanka, Tanzania, and South Korea [17] was used for genotyping PCR using the KOD One PCR Master (Toyobo, Osaka, Japan) and the following ERV-DC8 genotyping primers: Fe–57S (5'-TTAGG AATAAGCTC GGGGTAACT-3'), Fe–36S (5'-AACCGCTTGGTACA RTTCATAAGAG-3'), and Fe-54R (5'-GTAGGCTCATTGTTAGGAGAGAAAAA-3'). PCR was carried out using the following cycling conditions: 30 cycles of denaturation at 98 °C for 10 s, annealing at 60 °C for 5 s, and extension at 68 °C for 6 s. The resulting PCR products were analyzed by electrophoresis on a 1 % agarose gel.

2.11. Statistical analysis

Infection assay results and geographical correlations were analyzed using one-way analysis of variance, Student's t-test, or Fisher's exact test. Statistical significance was set at p < 0.05.

				30								
		Sig	nal peptide		7					VRA		
ERV-DC8	1	MKPPAGMVFL	WVLTSLGAGI	GAKIVKEENP	HQVYTLTWQI	YSQSGEVVWE	VQGNHALNTW	WPPLTPDFCQ	LAAGLDTWDI	PARSPKNLQS	YMGERIQQMT	100
ERV-DC14	1			G								100
ERV-DC10	1	.R.S.R	EV	R.AG						.DET	S.EGTSL.	100
FeLV-D Tv26	1			G								100
										VDD		
FRU-DC9	101	AUCCSSDTAD	CRIAOAFEVU		AUDCCOVEEV	FCSAWCCETT	CDAVWODTCC	WDI TUTURCY	TYPDDDCUTC	VYKKCTECVU	UNTODICIDI	200
ERV-DC14	101	ANGCOOT TAK	CIUDAQADI IV	CINDWINDIAI	AIICOGILLI	rebawgehii	GDAIWQIIDD	WDDIIIIKGI	INIDIDONIC	IIIIIIIIIII	IIWI DI DODI D	200
ERV-DC14	101	DO K WK	A EDD	N			 D	N	CODDR-	_VEDVDVMCD	 PD	100
ERV-DCIU	101	FQ	.AERD				· · · · · · K · · · ·		SCDDR-	-VERKKRISK	RD	200
FELV-D TY20	101											200
	201	KIMEMDOCKD	AT CHOMOVER	CI DEVI DOVD	DOTUTIVITVIV	TOUTHOUSUCD	NI UI ADOKAD		PRR	DIDIOMICDOI	CNDED	205
ERV-DC8	201	KITFTDSGKR	ALGWQIGIIW	GLKWILPGKD	RGIVLKIKLK	TDITIQUE	NLVLADQKAP	VQLAIPVQPP	RAPTQTPGIN	PVNSTLSPSL	GIPTP=====	295
ERV-DC14	201											295
ERV-DC10	199	• • • • • • • • • • •						A	RV.	····P····	A.APGPR	298
FeLV-D Ty26	201								• • • • • • • • • • •			295
		PRR										
ERV-DC8	295	PSRP	GTGDRLLNLV	QGVYLTLNLT	APNQTQDCWL	CLTAKPPYYQ	GVAIIGNFTN	HTNAPLRCST	TPRHGLTLTE	VTGHGLCIGK	IPPSHQNLCS	389
ERV-DC14	295											389
ERV-DC10	299	PPYPTS			Τ							398
FeLV-D Ty26	295				s <u></u>	<u> </u>						389
					CXX	(C			TM			
ERV-DC8	390	QTIPSVGQGP	YYLTAPNGTY	WVCNTGLTPC	ISLQVLNNTA	DYCILIELWP	KIFYHDSEYI	YGHYEPGG RF	RREPVSLTVA	LLLGGLTMGS	LAAGIGTGTA	489
ERV-DC14	390											489
ERV-DC10	399				ID			L	D			498
FeLV-D Ty26	390							<u></u>	<u></u>			489
								cleava	age site			
ERV-DC8	490	ALIETNQFKQ	LQIAMHSDIQ	ALEESISALE	RSLTSLSEVV	LQNRRGLDLL	FLQEGGL CAA	LKEECC FYAD	HTGIVRDSMA	KLRERLKQRQ	KLFESQQGWF	589
ERV-DC14	490											589
ERV-DC10	499											598
FeLV-D Ty26	490								L		QD	589
							_	CX _c C				
ERV-DC8	590	EGWYNKSPWF	TTLVSSLMGP	LILLLILMF	GPCILNRLVQ	FIRERLSVIQ	ALVLTQQYHQ	LRQFDAERPD	TIE 662			
ERV-DC14	590								662			
ERV-DC10	599			v.					671			
FeLV-D Tv26	590	F.R	T T	T T.		.VKD. M	T 0.	TK.Y.PDO	658			

011

Fig. 2. Amino acid sequence alignment of ERV-DC8 Env. Amino acid sequence alignment of the Env proteins of ERV-DC8 (in this study; LC597234), ERV-DC14 (AB674445), ERV-DC10 (AB674444), and FeLV-D TY26 (AB673428). SP, signal peptide; SU, surface unit; VRA, variable region A; VRB, variable region B; PRR, proline-rich region; TM, transmembrane subunit; R-X-R/K–R is the cleavage motif; CXXC and CX6CC are sites of covalent interaction.

Ethical approval

Animal studies were conducted in accordance with the guidelines for the care and use of laboratory animals of the Ministry of Education, Culture, Sports, Science, and Technology, Japan. All the experiments were approved by the Genetic Modification Safety Committee of Yamaguchi University, Japan.

2.12. Accession numbers

The nucleotide sequences reported herein were deposited in the DDBJ, EMBLE, and GenBank databases under the accession number LC597234.

3. Results

3.1. ERV-DC8 is infectious and replication-competent

PCR was performed using chromosomal DNA from domestic cats (cat ID: CB7, OY20, and OI32) [16], all of which carry ERV-DC8 at the heterologous locus. An approximately 9-kb band corresponding to the ERV-DC8 provirus was detected in all cats, and the ERV-DC8 proviruses from the domestic cats were molecularly cloned. A preliminary study was conducted using 293Lac and HEK293T cells to determine viral infectivity and replication. All clones were found to be infective. All clones were confirmed using genetic sequencing. The sequencing results were the same for all clones; consequently proving that the ERV-DC8 (OI32) clone was used in this study.

The infectivity of the ERV-DC8 (OI32) virus was evaluated in various

cell lines by producing it in 293Lac cells (Fig. 1A). The ERV-DC8 provirus was transfected into 293Lac cells and the supernatant was used as the viral source. HepG2 (human), KwDM (dog), Rat2 (rat), and 104C1 (guinea pig) cells exhibited viral infectivity ranging from approximately 10^{1} – 10^{3} infection units (IU)/mL. Infectivity was the highest in HepG2 cells. In contrast, no infection was observed in MDTF (mouse) cells (Fig. 1B). Western blotting was performed to detect viral proteins in cell lysates from 293T cells transfected with ERV-DC8. Western blotting yielded a 75-kD protein band corresponding to the Env of ERV-DC8 (Fig. 1C). Similarly, purified virions from the cell supernatants also revealed a 75-kD protein band corresponding to Env of ERV-DC8 (Fig. 1D). The polyclonal antibody used in this study was sensitive to ERV-DC10 detection. Overall, these findings indicated that ERV-DC8 is an infectious and replication-competent provirus.

3.2. Sequence analysis of ERV-DC8 (OI32)

The ERV-DC8 (OI32) nucleotide sequence was 8864 bp in length, consisting of a 5244 bp *gag-pol* and a 1990 bp *env* gene, and an intact ORF (Fig. 2), similar to the previously isolated ERV-DC8 IS10 clone, which was not replication-competent. A comparison of the ERV-DC8 OI32 and IS10 sequences revealed a one-base difference at position 3162 in the *pol* gene. ERV-DC8 OI32 had a guanine (G), whereas ERV-DC8 IS10 had a T at this position that located in the reverse transcriptase (RT) region of the *pol* gene (Fig. S1).

ERV-DC8 from cats ID CB7, and OY20 also contained guanine (G). The ERV-DC8 Env protein is composed of 662 amino acids and contains a putative signal peptide (SP), SU subunit, furin cleavage site, and TM subunit. It is structurally identical to ERV-DC14 Env, with only one



Fig. 3. Analysis of the ERV-DC8TA mutant. (A) Schematic representation of the ERV-DC8 and ERV-DC8TA mutants. Green asterisks indicate nucleotide position. Thymine (T) was replaced with adenine (A) at nucleotide positions 280 in the 5'LTR and 8594 in the 3'LTR of ERV-DC8 (OI32). (B) Infection assay of the ERV-DC8TA mutant. HEK293T (human) cells were infected with the indicated viruses. (C) Western blot analysis of the ERV-DC8TA mutant. The cell lysates from HEK293T cells transfected with the indicated ERV-DC8 to detect ERV-DC8 Env protein 3 days after transfection. Anti-FeLV gp70 was used for western blotting, whereas anti-human β -actin was used as the control. (D) Infection assay of the ERV-DC8TA mutant in feline cell lines, AH927 and CRFK cells. The infectious units were determined by counting the number of log10-galactosidase (LacZ)-positive cells per milliliter of virus. Mean virus infection titers with standard deviations were determined from three independent experiments. The data were statistically analyzed by one-way analysis of variance (*p < 0.0001). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

amino acid difference in the SU subunit at position 28. Additionally, ERV-DC8 shared a 96.5 % amino acid sequence with FeLV-D/Ty26 Env (Fig. 2).

3.3. Single nucleotide polymorphism (SNP) in the LTRs of ERV-DC8

The nucleotides at positions 280 in the 5'LTR and 8594 in the 3'LTR of ERV-DC8 (OI32) were both T, indicating that the SNP affected the LTR promoter activity in ERV-DC [25]. Therefore, an ERV-DC8TA mutant, in which T was replaced with A, was constructed and tested for infectivity and viral expression (Fig. 3A). The viral titer of the ERV-DC8TA mutant was approximately 4-fold higher than that of ERV-DC8 in HEK-293T cells (Fig. 3B). Furthermore, ERV-DC8 Env protein expression was higher in ERV-DC8TA than in wild-type ERV-DC8 (Fig. 3C). ERV-DC14 and ERV-DC14TA were used as controls as previously described [25]. Furthermore, ERV-DC8TA inoculation into feline cell lines (AH927 and CRFK) let to infectivity in both cell lines (Fig. 3D). Our results suggest that the LTR promoter activity in ERV-DC8 is affected by a single nucleotide change from T to A.

3.4. Transmission electron microscopy (TEM) analysis

TEM analysis of HEK293T cells infected with ERV-DC8TA revealed 90–100-nm viral particles (Fig. 4). This result suggests the viral budding morphology, characterizing the virus as a type C retrovirus or *Gammaretrovirus*.

4. Receptor for ERV-DC8

Previous reports have demonstrated that the ERV-DC8 Env-pseudotyped virus is in the same interference group as FeLV-D [27]. In this study, we performed an interference assay using the ERV-DC8 OI32 replication-competent virus. The viral titer of ERV-DC8 was found to be 3.3×10^2 IU/mL when HEK293T/mock cells were infected, compared to 1.3×10^0 IU/mL when HEK293T/FeLV-D cells were infected. The ERV-DC8 virus significantly interfered with FeLV-D infection (p < 0.05) (Fig. 5A). The results indicated that ERV-DC8 belongs to the same interference group as FeLV-D.

FeLV-D and ERV-DC genotype I have previously been reported to use feCTR1 as a receptor [26,28]. To confirm the receptor for ERV-DC8, the virus was inoculated into MDTF-feCTR1 cells. MDTF-feCTR1 permitted ERV-DC8 infection (Fig. 5B). Overall, these findings indicate that ERV-DC8 uses the same receptor as FeLV-D, that is, the feCTR1.

4.1. Insertional polymorphism of ERV-DC8

Previously, we investigated the prevalence of ERV-DC8 in domestic cats in Japan (n = 244) and Spain (n = 35) [29]. Our findings revealed a high frequency of ERV-DC8 in domestic cats from Japan (77.5 %) and Spain (65.7 %) [7,29]. Here, we further investigated the frequency of ERV-DC8 in domestic cats using PCR primers based on unique genomic DNA flanking sequences or with secondary primers based on the proviral sequence (Fig. 6A). PCR revealed that the provirus was not present on



Fig. 4. Transmission electron microscopy (TEM). HEK293T cells transfected with ERV-DC8TA mutant were cultured for 1 week, fixed, and analyzed by TEM. (A, B) The cells demonstrated viral budding, and (C, D) the viral particles. The scale bar indicates a length of 200 nm.



Fig. 5. Interference assay with FeLV-D and receptor usage of ERV-DC8. (A) HEK293T cells persistently infected with FeLV-D were inoculated with ERV-DC8 containing a retrovirus vector carrying a LacZ marker. (B) MDTF-CTR1 cells were inoculated with ERV-DC8TA mutant carrying a LacZ marker. MDTF-vector indicates the control. The infectious units were determined by counting the number of log10-galactosidase (LacZ)-positive cells per milliliter of virus. Mean virus infection titers with standard deviations were determined from three independent experiments. The data were statistically analyzed by student-t test (*p < 0.005).

either chromosome (indicated by the -/- symbol), was present as homozygous (indicated by the +/+ symbol), or was present as heterozygous (indicated by the \pm symbol) (Fig. 6B). PCR was performed to detect ERV-DC8 in domestic cats from Tanzania (n = 49), Vietnam (n = 19), South Korea (n = 19), and Sri Lanka (n = 35). The frequency of ERV-DC8 ranged from 52.6 % to 85.8 % in domestic cats from these four countries (Fig. 6C). The frequency of ERV-DC8 was the highest among domestic cats in Tanzania (85.8 %) and the lowest among domestic cats in Vietnam (52.6 %) and South Korea (52.6 %) (Fig. 6C). The frequency of ERV-DC8 in Asia was the highest among domestic cats in Japan [29], with similar proportions observed in Vietnam and South Korea. The prevalence of ERV-DC8 varied significantly among the domestic cats in the countries studied. There were significant differences between Tanzania and Sri Lanka (p = 0.0375), Tanzania and South Korea (p =0.0087), Tanzania and Vietnam (p = 0.0087), Vietnam and Japan (p =0.024), and South Korea and Japan (p = 0.024). Collectively, these results suggest that ERV-DC8 is highly integrated into domestic cats in these countries.

5. Discussion

In this study, we characterized ERV-DC8 by examining its genetic structure, sequence differences from related ERVs, and infectious abilities. We established ERV-DC8 as infectious and replication-competent. Recently four ERV-DC8 have been identified as infectious and replication-competent: ERV-DC8 (in this study; LC597234) and ERV-DC14 [25] are classified as GI, and ERV-DC10 and ERV-DC18 are classified as GIII [7]. Only one cat family has been shown to harbor ERV-DC18, which contains a single nucleotide difference compared to



Fig. 6. Insertional polymorphism of ERV-DC8. (A) PCR for pre-integration site (PIS) detection and provirus using the indicated PCR primers. Primer pairs Fe–57S and Fe-54R detected a PIS and/or full-length provirus. (B) ERV-DC8 detection and genotyping. Band sizes of 0.5 kbp and 1.3 kbp represent the pre-integration site and proviral insertional polymorphic sites, respectively. -/-, no copy of the provirus present on either chromosome; +/+, proviral copy present on both chromosomes (homozygous); +/-, provirus copy present on one of two chromosomes (heterozygous). (C) Prevalence of ERV-DC8 in domestic cats from different countries. +/+, copy present on both chromosomes (homozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, orange); +/-, copy present on one of two chromosomes (heterozygous, blue). The data were analyzed using Fisher's exact test (*p < 0.05). Data from Japan and Spain was obtained from a previous report [29]. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

ERV-DC10, suggesting that it might be internalized via reinfection with ERV-DC10 [7]. ERV-DC8 and ERV-DC14 differ in sequence by 24 nucleotides. Both ERV-DC8 and ERV-DC14 exhibit a single nucleotide difference in the sequences of the 5' and 3'LTRs. Therefore, sequence analysis indicates that ERV-DC is a young ERV [7,15]. Recent studies have shown that an SNP exists in the Env of ERV-DC14 in European wildcats (*Felis silvestris*), resulting in replication incompetence [29]. Our Western blot analysis and viral infection assays (Fig. 3) showed an increased level of replication of the ERV-DC8TA mutant compared to that of the wild type due to the change in promoter activity (Fig. 3B). This phenomenon is similar to that observed in ERV-DC14, and the attenuated promoter activity may be a mechanism of ERV inactivation.

In investigating the ability of the ERV-DC8 provirus to infect various hosts, we found that ERV-DC8 provirus carrying LacZ infected cells derived from humans (HEK293T and HepG2), cats (AH927 and CRFK), dogs (KwDM), rats (Rat2), and guinea pigs (104C1), but not from mice (MDTF). The previously cloned ERV-DC8 (IS10) was replicationincompetent because of a nucleotide change at position 3162 in the reverse transcriptase gene [7], which we compared with our clone ERV-DC8 (OI32) in this study. These results suggest that ERV-DC8 may be a potential threat to human and animal health.

Our findings provide valuable insights into the insertional polymorphism of ERV-DC8. ERV-DC8 insertional polymorphism frequency ranged from 53 to 86 % in domestic cats from several countries (Japan [29], Spain, Tanzania, Vietnam, South Korea, and Sri Lanka). Although a geographical relationship could not be determined with certainty in this study, ERV-DC8 is spreading among domestic cats worldwide. However, ERV-DC8 was not integrated into European wildcats [29]. We hypothesize that ERV-DC8 may not have integrated into the same ancestral line of cats. The integrated ERV-DC8 ancestor may have been present in the lineage of domestic cats but absent in that of wildcats lineage.

Additionally, a viral interference assay demonstrated that infectious ERV-DC8 belongs to the FeLV-D interference group and has the same receptors as FeLV-D, as confirmed by infecting MDTF-feCTR1 cells (Fig. 5A and B). FeLV-D is generated using the *env* genes of FeLV and the recombination of ERV-DC GI to acquire a new viral property [7,15]. FeLV-D is associated with lymphoma/leukemia induction [12]. We speculate that ERV-DC8 may represent a major contributor to the emergence of FeLV-D because of the high frequency of ERV-DC8 in domestic cats.

Several animals such as cats and pigs have been reported to have infectious ERVs [7,30], which is in line with our findings of ERV-DC8 in domestic cats. Activation of infectious ERVs is potentially harmful to the body. The presence of infectious ERVs in domestic cats can be dangerous to the host because they contribute to the emergence of several FeLV subtypes [12]. Mice have also been reported to have infectious ERVs, which can lead to tumors in patients with TLR7 deficiency or immunodeficiency, owing to ERV activation [31]. APOBEC, an antiretroviral molecule, suppresses the emergence of pathogenic ERVs [32]. Thus, host immunity and defense mechanisms regulate ERV activation. Furthermore, even in the presence of such ERV, epigenetic control prevents the virus from being expressed by losing its transcriptional activity [4]. In contrast, some ERVs have been reported to benefit the host; for example, Syncytin-1 aids placentation [33], Refrex-1 promotes cellular copper homeostasis [34], and resistance conference against retrovirus infection in several species, including cats and primates [26]. The existence of ERVs in hosts can be attributed to several factors-harmful and beneficial.

In conclusion, our findings establish the existence of infectious ERV-DC8 in domestic cats. ERV-DC8 may play a major role in the emergence of FeLV-D, which is pathogenic to the host (cats). ERV-DC8 dynamics must be further studied for feline health management. This study also highlighted the role of ERVs and the evolutionary relationship between viruses and their hosts. Future research should focus on elucidating the mechanisms of ERV activation and its impact on host immunity to develop strategies for mitigating risks while harnessing potential benefits.

This study was funded by the Japan Society for the Promotion of Science, KAKENHI (grant numbers 20H03152 and 23H02393 to KN).

CRediT authorship contribution statement

Didik Pramono: Writing – review & editing, Writing – original draft, Project administration, Investigation, Formal analysis, Data curation. Yutaro Muto: Writing – original draft, Validation, Investigation, Formal analysis, Data curation. Yo Shimazu: Investigation. R.M.C. Deshapriya: Resources, Investigation. Isaac Makundi: Investigation. María-Cruz Arnal: Investigation. Daniel Fernández de Luco: Investigation. Minh Ha Ngo: Investigation. Ariko Miyake: Investigation. Kazuo Nishigaki: Writing – review & editing, Writing – original draft, Validation, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Conceptualization.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgments

We are grateful to Dr. Yoshinao Kubo for providing the MDTF cells and Dr. Toshio Kitamura for providing the PLAT-GP cells and pMxs retroviral vector. We thank Editage (www.editage.jp) for the English language editing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrc.2024.150521.

References

- E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, et al., Initial sequencing and analysis of the human genome, Nature 409 (6822) (2001) 860–921.
- [2] J.U. Pontius, J.C. Mullikin, D.R. Smith, K. Lindblad-Toh, S. Gnerre, M. Clamp, et al., Initial sequence and comparative analysis of the cat genome, Genome Res. 17 (11) (2007) 1675–1689.
- [3] R.H. Waterston, K. Lindblad-Toh, E. Birney, J. Rogers, J.F. Abril, P. Agarwal, et al., Initial sequencing and comparative analysis of the mouse genome, Nature 420 (6915) (2002) 520–562.
- [4] W.E. Johnson, Origins and evolutionary consequences of ancient endogenous retroviruses, Nat. Rev. Microbiol. 17 (6) (2019) 355–370.
- [5] R.K. Slotkin, R. Martienssen, Transposable elements and the epigenetic regulation of the genome, Nat. Rev. Genet. 8 (4) (2007) 272–285.
- [6] R.M. McAllister, M. Nicolson, M.B. Gardner, R.W. Rongey, S. Rasheed, P.S. Sarma, et al., C-type virus released from cultured human rhabdomyosarcoma cells, Nat. New Biol. 235 (53) (1972) 3–6.
- [7] Y. Anai, H. Ochi, S. Watanabe, S. Nakagawa, M. Kawamura, T. Gojobori, et al., Infectious endogenous retroviruses in cats and emergence of recombinant viruses, J. Virol. 86 (16) (2012) 8634–8644.
- [8] C.A. Kozak, Origins of the endogenous and infectious laboratory mouse gammaretroviruses, Viruses 7 (1) (2014) 1–26.

- [9] R.S. Treger, S.D. Pope, Y. Kong, M. Tokuyama, M. Taura, A. Iwasaki, The lupus susceptibility locus Sgp3 encodes the suppressor of endogenous retrovirus expression SNERV, Immunity 50 (2) (2019), 334-47.e9.
- [10] R. Sankowski, J.J. Strohl, T.S. Huerta, E. Nasiri, A.N. Mazzarello, C. D'Abramo, et al., Endogenous retroviruses are associated with hippocampus-based memory impairment, Proc. Natl. Acad. Sci. U. S. A. 116 (51) (2019) 25982–25990.
- [11] K. Hartmann, R. Hofmann-Lehmann, What's new in feline leukemia virus infection, Vet Clin North Am Small Anim Pract. 50 (5) (2020) 1013–1036.
- [12] M.H. Ngo, L. AbuEed, J. Kawasaki, N. Oishi, D. Pramono, T. Kimura, et al., Multiple recombination events between endogenous retroviral elements and feline leukemia virus, J. Virol. (2024) e0140023.
- [13] W. Beyer, R. Möhring, B. Drescher, U. Nötzel, S. Rosenthal, Molecular cloning of an endogenous cat retroviral element (ECE 1)–a recombinant between RD-114 and FeLV-related sequences. Brief report, Arch. Virol. 96 (3–4) (1987) 297–301.
- [14] A.C. van der Kuyl, J.T. Dekker, J. Goudsmit, Discovery of a new endogenous type C retrovirus (FcEV) in cats: evidence for RD-114 being an FcEV(Gag-Pol)/baboon endogenous virus BaEV(Env) recombinant, J. Virol. 73 (10) (1999) 7994–8002.
- [15] J. Kawasaki, K. Nishigaki, Tracking the continuous evolutionary processes of an endogenous retrovirus of the domestic cat: erv-dc, Viruses 10 (4) (2018).
- [16] S. Watanabe, M. Kawamura, Y. Odahara, Y. Anai, H. Ochi, S. Nakagawa, et al., Phylogenetic and structural diversity in the feline leukemia virus env gene, PLoS One 8 (4) (2013) e61009.
- [17] M.H. Ngo, T. Soma, H.Y. Youn, T. Endo, I. Makundi, J. Kawasaki, et al., Distribution of infectious endogenous retroviruses in mixed-breed and purebred cats, Arch. Virol. 165 (1) (2020) 157–167.
- [18] D.P. Aden, A. Fogel, S. Plotkin, I. Damjanov, B.B. Knowles, Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line, Nature 282 (5739) (1979) 615–616.
- [19] R.B. DuBridge, P. Tang, H.C. Hsia, P.M. Leong, J.H. Miller, M.P. Calos, Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system, Mol. Cell Biol. 7 (1) (1987) 379–387.
- [20] Characterization of cat cell cultures for expression of retrovirus, FOCMA and endogenous sarc genes, in: S. Rasheed, M. Gardner (Eds.), Proceedings of the Third International Feline Leukemia Virus Meeting, 1980.
- [21] R.A. Crandell, C.G. Fabricant, W.A. Nelson-Rees, Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK), In Vitro 9 (3) (1973) 176–185.
- [22] W.C. Topp, Normal rat cell lines deficient in nuclear thymidine kinase, Virology 113 (1) (1981) 408–411.
- [23] C.H. Evans, J.A. DiPaolo, Neoplastic transformation of Guinea pig fetal cells in culture induced by chemical carcinogens, Cancer Res. 35 (4) (1975) 1035–1044.
- [24] M.R. Lander, S.K. Chattopadhyay, A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses, J. Virol. 52 (2) (1984) 695–698.
- [25] K. Kuse, J. Ito, A. Miyake, J. Kawasaki, S. Watanabe, I. Makundi, et al., Existence of two distinct infectious endogenous retroviruses in domestic cats and their different strategies for adaptation to transcriptional regulation, J. Virol. 90 (20) (2016) 9029–9045.
- [26] A. Miyake, M.H. Ngo, S. Wulandari, M. Shimojima, S. Nakagawa, J. Kawasaki, et al., Convergent evolution of antiviral machinery derived from endogenous retrovirus truncated envelope genes in multiple species, Proc. Natl. Acad. Sci. U.S. A. 119 (26) (2022) e2114441119.
- [27] J. Ito, S. Watanabe, T. Hiratsuka, K. Kuse, Y. Odahara, H. Ochi, et al., Refrex-1, a soluble restriction factor against feline endogenous and exogenous retroviruses, J. Virol. 87 (22) (2013) 12029–12040.
- [28] S. Tury, D. Giovannini, S. Ivanova, J. Touhami, V. Courgnaud, J.L. Battini, Identification of copper transporter 1 as a receptor for feline endogenous retrovirus ERV-DC14, J. Virol. 96 (12) (2022) e0022922.
- [29] M.H. Ngo, M. Arnal, R. Sumi, J. Kawasaki, A. Miyake, C.K. Grant, et al., Tracking the fate of endogenous retrovirus segregation in wild and domestic cats, J. Virol. 93 (24) (2019).
- [30] C. Patience, Y. Takeuchi, R.A. Weiss, Infection of human cells by an endogenous retrovirus of pigs, Nat. Med. 3 (3) (1997) 282–286.
- [31] E.P. Browne, Toll-like receptor 7 controls the anti-retroviral germinal center response, PLoS Pathog. 7 (10) (2011) e1002293.
- [32] R.S. Treger, M. Tokuyama, H. Dong, K. Salas-Briceno, S.R. Ross, Y. Kong, et al., Human APOBEC3G prevents emergence of infectious endogenous retrovirus in mice, J. Virol. 93 (20) (2019).
- [33] S. Mi, X. Lee, X. Li, G.M. Veldman, H. Finnerty, L. Racie, et al., Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis, Nature 403 (6771) (2000) 785–789.
- [34] S. Tury, L. Chauveau, A. Lecante, V. Courgnaud, J.L. Battini, A co-opted endogenous retroviral envelope promotes cell survival by controlling CTR1mediated copper transport and homeostasis, Cell Rep. 42 (9) (2023) 113065.